Govt likely to reduce private sector's 25% Covid-19 vaccine quota

Vaccine makers, the government has indicated, can provide doses to the private sector according to demand and the remaining would be bought by the government

vaccination, coronavirus, covid-19, vaccine
Private hospitals also feel that with the Centre deciding to increase the free vaccinations to 75 per cent, the number of people willing to pay for a jab has reduced significantly.
Ruchika ChitravanshiSohini Das New Delhi / Mumbai
3 min read Last Updated : Aug 05 2021 | 1:55 AM IST
The Centre has indicated that with lower utilisation of Covid vaccines by the private sector, its 25 per cent quota may not be necessary.
 
Health minister Mansukh Mandaviya told Rajya Sabha, in response to a question by MP Sushil Kumar Modi, that the government took over 7-9 per cent of the private sector’s quota since it had not been utilised.
 
Vaccine makers, the government has indicated, can provide doses to the private sector according to demand and the remaining would be bought by the government.
 
If private players do not pick up 25 per cent of the vaccines produced, manufacturers may face financial losses. The prices of Covishield and Covaxin are Rs 600 per dose and Rs 1,200 per dose, respectively, for the private sector. The Centre procures Covishield at Rs 215 per dose and Covaxin at Rs 225 per dose, inclusive of taxes.
 
The revised guidelines for vaccine management came into effect from June 21. The government would procure 75 per cent of the vaccines being produced in the country and make them available to states for free for all above 18 years of age. The remaining 25 per cent could be directly accessed by the private hospitals.
 
A source in a vaccine manufacturing firm said that the government has indicated that vaccine makers need not compulsorily hold 25 per cent of their monthly production for the private sector, but continue to supply based on orders placed.

“We usually indicate our production plan to the government in advance, which helps it to plan the procurement and distribution. We will continue to do so. The Centre also knows about a consolidated demand from the private sector, as state governments collate the demand from the private sector and indicate this to the Centre,” said an executive.

The person added that if this demand estimation shows that the demand from the private sector is less than 25 per cent of the total volumes, then vaccine makers will supply private hospitals according to orders placed.
 
This also implies that the Centre can procure more than the 75 per cent quota that it has allocated for government purchase, if the demand from the private sector is less.
 
Another executive at a vaccine making company said, “The private sector’s vaccination drive is now spreading beyond metros. Demand would be there. Some hospitals had created a stockpile, and are thus ordering according to their consumption pattern,” the executive said.
 
At least two leading hospitals said they have not yet heard from either the Centre or vaccine makers about any policy change. “We continue to place orders based on our requirements,” said a senior executive.
 
Private hospitals also feel that with the Centre deciding to increase the free vaccinations to 75 per cent, the number of people willing to pay for a jab has reduced significantly. “Consequently, the private sector has been able to only vaccinate about 7 per cent of the people in May. Government buying all the remaining doses would lead to faster vaccination of the adult population, and hopefully, lead to minimising effects of the third wave,” said Harsh Mahajan, president, Nathealth, a healthcare body.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus Vaccineprivate sectorVaccination

Next Story